Autoimmune Disease Testing Market By Product Type (Instruments, Consumables and kits) , By Disease Type (Rheumatoid Arthritis, Systemic Lupus Erythematous, Scleroderma, Vasculitis, Inflammatory Bowel Disease, Others) By Test Type (Antibodies and Immunolgi

Autoimmune Disease Testing Market By Product Type (Instruments, Consumables and kits) , By Disease Type (Rheumatoid Arthritis, Systemic Lupus Erythematous, Scleroderma, Vasculitis, Inflammatory Bowel Disease, Others) By Test Type (Antibodies and Immunolgic Test, Inflammatory Markers, Routine Laboratory Tests, Anti-Thyroglobulin Antibody, Others) By End User (Hospitals and Clinics, Clinical Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

The autoimmune disease testing market was valued at $5.3 billion in 2023, and is projected to reach $12.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.
Autoimmune disease testing involves diagnosing and managing a wide range of autoimmune disorders by identifying specific autoantibodies and other biomarkers in the blood that indicate the presence of an autoimmune condition. These tests are essential in detecting a wide range of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. By analyzing specific biomarkers and antibodies in the blood, healthcare professionals can accurately diagnose these conditions, enabling timely and targeted treatment. Early detection through autoimmune testing is vital for managing symptoms, slowing disease progression, and improving patient outcomes.
Alarming increase in incidence of autoimmune diseases globally acts as the primary driver of the global autoimmune disease testing market, as these individuals require accurate and early diagnosis. According to a study published by the National Institutes of Health in 2022, autoimmune diseases were prevalent among approximately 23.5 million Americans, indicating the importance of effective diagnostic testing. In addition, surge in geriatric population significantly contributes toward the growth of the global market. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. With increasing aged population, the incidence of chronic conditions is expected to rise significantly. A 2021 report published by the Centers for Disease Control and Prevention highlights that autoimmune diseases are among the leading causes of death for women under the age of 65. This is attributed to the fact that as the population ages, there is an increased demand for diagnostic tests to monitor and manage age-related diseases, thereby boosting the market for autoimmune disease testing. Furthermore, increase in public awareness about autoimmune diseases and the importance of early detection and rise in healthcare expenditure foster the market growth. Rise in use of point-of-care testing devices for quicker and more convenient results and shift in preference toward telemedicine and mobile health apps for remote testing and monitoring are the key trends that significantly people the market growth. However, high cost associated with advanced diagnostic tests and technologies acts as the primary barrier for the market growth. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, extensive research in identifying new biomarkers associated with autoimmune diseases has led to the development of more specific and sensitive tests, which is expected to provide lucrative opportunities for the market growth. In addition, increase in use of cutting-edge technologies, such as next-generation sequencing and multiplex assays to enhance the accuracy and efficiency of autoimmune disease testing is anticipated to open new avenues for the market growth in the coming years.
The global autoimmune disease testing market is segmented on the basis of product type, disease type, test type, end user, and region. On the basis of product type, the market is fragmented into instruments, consumables, and kits. By disease type, it is categorized into rheumatoid arthritis, systemic lupus erythematous, scleroderma, vasculitis, inflammatory bowel disease, and others. Depending on test type, it is fragmented into antibodies and immunologic test, inflammatory markers, routine laboratory tests, anti-thyroglobulin antibody, and others. As per end user, it is classified into hospitals & clinics, clinical laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product type, the consumables & kits segment is expected to dominate the market from 2024 to 2033.
On the basis of disease type, the rheumatoid arthritis segment is projected to garner a significant market share in the coming years.
Depending on test type, the routine laboratory tests segment is anticipated to be the major shareholder in the autoimmune disease testing market during the forecast period.
As per end user, clinical laboratories is likely to emerge as a leading segment in the near future.
Region wise, North America is poised to maintain its leadership in the autoimmune disease testing market by 2033.

Competition Analysis

Competitive analysis and profiles of the major players in the global autoimmune disease testing market include F. Hoffmann-La Roche Ltd, Siemens , Thermo Fisher Scientific Inc., Quest Diagnostics, Abbott, Werfen, S.A., Trinity Biotech, Bio-Rad Laboratories, Inc., Grifols, S.A., and Exagen Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Key Market Segments

By Product Type

Instruments
Consumables and kits

By Disease Type

Rheumatoid Arthritis
Systemic Lupus Erythematous
Scleroderma
Vasculitis
Inflammatory Bowel Disease
Others

By Test Type

Antibodies and Immunolgic Test
Inflammatory Markers
Routine Laboratory Tests
Anti-Thyroglobulin Antibody
Others

By End User

Hospitals and Clinics
Clinical Laboratories
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffmann-La Roche Ltd
Siemens
Thermo Fisher Scientific Inc.
Quest Diagnostics
Abbott
Werfen, S.A.
Trinity Biotech
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Exagen Inc.